Enriching for tumor-reactive CD8 TIL using CD39/103 markers: Clinical implications

Authors

A Weinberg, Providence

Document Type

Presentation

Publication Date

8-22-2022

Keywords

oregon; portland; chiles

Area of Special Interest

Cancer

Specialty/Research Institute

Oncology

Comments

Cell Therapy Durbility Response Summit; 2022 August 22; Boston, MA.